2 results match your criteria: "Department of Dermatology and HMC Translational Research Institute[Affiliation]"
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis.
Dermatol Ther (Heidelb)
October 2024
Pfizer Inc, New York, NY, USA.
Article Synopsis
- The ALLEGRO study showed that ritlecitinib, a JAK3/TEC inhibitor, is effective and safe for treating alopecia areata in patients aged 12 and older with significant scalp hair loss.
- A post hoc analysis examined how previous alopecia treatments affected treatment outcomes using the Severity of Alopecia Tool (SALT) in patients taking ritlecitinib.
- Results indicated that prior use of intralesional corticosteroids improved short-term outcomes, while systemic immunosuppressants worsened them, but overall, previous treatment history did not significantly influence long-term responses to ritlecitinib.
Understanding the Burden of Atopic Dermatitis in Africa and the Middle East.
Dermatol Ther (Heidelb)
June 2019
Department of Dermatology and HMC Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intensely pruritic lesions. The prevalence of atopic dermatitis is increasing in developing regions, including Africa and the Middle East. However, these regions are underrepresented in the dermatology literature, and a better understanding of the growing burden of atopic dermatitis in Africa and the Middle East is necessary.
View Article and Find Full Text PDF